FLT3 and acute promyelocytic leukemia: A more recent study published in 2021 reported a 90-patient APL cohort treated with ATRA plus ATO, and FLT3-ITD-positive patients had significantly higher WBC counts at diagnosis and were enriched in the Sanz high-risk group [63].